Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXaar Regulatory News (XAR)

Share Price Information for Xaar (XAR)

Share Price is delayed by 15 minutes
Get Live Data
132.00    -3.50 (-2.58%)
Bid:
133.00
Ask:
139.50
Spread: 6.50 (4.887%)
Market Cap: £103.58m
XAR Live PriceLast checked at - London Stock Exchange

Intraday Xaar Share Chart

Board Change

23 Feb 2024 10:30

RNS Number : 1814E
Xaar PLC
23 February 2024
 

23 February 2024

Xaar plc

Board Change

Xaar plc, ("the Company" or "Xaar"), a leading inkjet printing technology group, announces today the appointment of Stuart Widdowson to the Board as a Non-Executive Director effective from 27 February 2024.

Mr Widdowson is appointed as a representative of Odyssean Capital LLP ("Odyssean"), pursuant to a relationship agreement between the Company and Odyssean. The key terms are summarised in the notes below.

Mr Widdowson is the Managing Partner of Odyssean Capital, which he founded in 2017. From 2009 until 2017, he was lead fund manager of Strategic Equity Capital plc, which experienced a turnaround in its performance and rating during his tenure. He began his career as a strategy consultant undertaking commercial due diligence and strategy projects for private equity and corporate clients, before working for HgCapital, a leading private equity investor.

As at the last practicable date the total shareholding of funds managed by Odyssean Capital was 13,175,000 ordinary shares in the Company ("Ordinary Shares") representing approximately 16.6 per cent. of the Company's share capital. Additionally, Mr Widdowson beneficially owns 25,000 Ordinary Shares and the joint venture partner of Odyssean Capital, Harwood Capital, owns 1,050,000 Ordinary Shares.

Notes:

A summary of the key terms of the Relationship Agreement is as follows:

· Xaar has granted Odyssean the right to appoint Mr Widdowson to be a Director of the Company for appointment to the Board (the "Nominated Director") for so long as Odyssean has the right to exercise at least 10% or more of the Company's ordinary shares or voting rights attaching to the ordinary shares;

· Odyssean undertakes to, inter alia: (1) conduct all transactions and relationships with any member of Xaar's group on an arm's length basis; (2) not take any action which would have the effect of preventing Xaar or any member of Xaar's group from carrying on business independently of Odyssean or its associates; (3) not influence the day-to-day running of the Company (save through Mr Widdowson's role as the Nominated Director) and (4) not vote to prevent Xaar being managed in accordance with the principles of good governance set out in the UK Corporate Governance Code; and

· the Relationship Agreement will terminate (1) on the date upon which Odyssean ceases to hold at least 10% of the ordinary shares of the Company or the voting rights attaching to the ordinary shares of the Company; (2) on six months' notice written notice by either party at any time or immediately upon written notice in the event of a material breach of the Relationship Agreement; or (3) in the event that the Company's ordinary shares cease to be listed on the Official List or another recognised UK stock exchange.

Pursuant to Listing Rule 9.6.13, it is confirmed that Mr Widdowson was a director and shareholder of Durendal Limited, a fund management business, which was wound up in 2015. His shareholding was acquired by the majority shareholder and the cash was distributed to all shareholders before the company was voluntarily liquidated.

There is no additional information required to be disclosed pursuant to Listing Rule 9.6.13 in relation to the appointment of Stuart Widdowson to the Board.

Enquiries:

Xaar plc

+44 (0) 1223 423 663 

Ian Tichias, Chief Financial Officer

John Mills, Chief Executive Officer

 

Teneo Communications

Giles Kernick

Olivia Lucas

+44 (0) 207 353 4200

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOATTMPTMTTTBFI
Date   Source Headline
13th Mar 200810:21 amRNSDividend Payment Date
13th Mar 20087:01 amRNSFinal Results
19th Feb 20087:00 amRNSNotice of Final Results
8th Feb 20087:00 amRNSCustomer product launch
30th Jan 20087:00 amRNSDirectorate Change
29th Jan 20087:01 amRNSControl change for partner
10th Jan 20087:01 amRNSYear end trading update
9th Jan 20087:00 amRNSHolding(s) in Company
4th Jan 20083:59 pmRNSTotal Voting Rights
2nd Jan 20089:53 amRNSHolding(s) in Company
11th Dec 200712:25 pmRNSHolding(s) in Company
6th Dec 20075:17 pmRNSTotal Voting Rights
30th Nov 200710:26 amRNSHolding(s) in Company
30th Nov 20077:00 amRNSHolding(s) in Company
27th Nov 200710:12 amRNSHolding(s) in Company
31st Oct 20078:30 amRNSHolding(s) in Company
17th Oct 20076:36 pmRNSHolding(s) in Company
15th Oct 20077:00 amRNSAppointment of Director
5th Oct 20075:46 pmRNSDirector/PDMR Shareholding
12th Sep 20077:01 amRNSInterim Results
11th Sep 20077:03 amRNSNew customer product launches
4th Sep 20075:39 pmRNSTotal Voting Rights
3rd Sep 20077:02 amRNSNotice of Interim Results
21st Aug 20075:29 pmRNSHolding(s) in Company
17th Aug 20076:00 pmRNSHolding(s) in Company
17th Aug 20075:40 pmRNSHolding(s) in Company
6th Aug 20077:00 amRNSDirector/PDMR Shareholding
2nd Aug 20074:30 pmRNSTotal Voting Rights
17th Jul 20077:00 amRNSAppointment of R&D Director
13th Jul 200711:05 amRNSHolding(s) in Company
11th Jul 20077:00 amRNSDirector/PDMR Shareholding
11th Jul 20077:00 amRNSTotal Voting Rights
10th Jul 20077:00 amRNSPeriod End Trading Statement
9th Jul 20075:45 pmBUSDutton Associates Announces Investment Opinion: Xaar Plc Rated Buy in Update Report by Dutton Associates
4th Jun 200710:51 amRNSHolding(s) in Company
24th May 20076:11 pmRNSDirector/PDMR Shareholding
24th May 20071:10 pmRNSHolding(s) in Company
23rd May 20077:00 amRNSFacility visit
16th May 20077:01 amRNSAppointment of Chairman
14th May 20077:00 amRNSDirector/PDMR Shareholding
10th May 20076:05 pmRNSDirector/PDMR Shareholding
9th May 20076:19 pmRNSDirector/PDMR Shareholding
1st May 20076:24 pmRNSDirector/PDMR Shareholding
1st May 200711:37 amRNSHolding(s) in Company
24th Apr 200710:20 amRNSDirector/PDMR Shareholding
23rd Apr 200712:56 pmRNSResult of AGM
23rd Apr 20077:01 amRNSAGM Trading Update
13th Apr 20075:00 pmBUSDutton Associates Announces Investment Opinion: Xaar plc Buy Rating Maintained In Update Coverage By Dutton Associates
11th Apr 200711:55 amRNSAnnual Information Update
29th Mar 20071:27 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.